2023
DOI: 10.1186/s12951-023-01833-2
|View full text |Cite
|
Sign up to set email alerts
|

Ratiometric electrochemical OR gate assay for NSCLC-derived exosomes

Abstract: Non-small cell lung cancer (NSCLC) is the most common pathological type of LC and ranks as the leading cause of cancer deaths. Circulating exosomes have emerged as a valuable biomarker for the diagnosis of NSCLC, while the performance of current electrochemical assays for exosome detection is constrained by unsatisfactory sensitivity and specificity. Here we integrated a ratiometric biosensor with an OR logic gate to form an assay for surface protein profiling of exosomes from clinical serum samples. By using … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 79 publications
0
4
0
Order By: Relevance
“…48 Furthermore, the NPELDI MS featured desirable detection duration (on the scale of seconds), trace biofluid consumption (at least 500 nL), and an affordable price ($3/test). To date, the studies generally focus on the targeted quantitation of specific metabolites, 49,50 hardly collecting comprehensive fingerprint information. By harnessing the desirable detection duration, biofluid consumption, and data stability, the NPELDI MS has adequate reliability in comprehensive metabolic profiling and biomarker discovery in the next stage.…”
Section: Resultsmentioning
confidence: 99%
“…48 Furthermore, the NPELDI MS featured desirable detection duration (on the scale of seconds), trace biofluid consumption (at least 500 nL), and an affordable price ($3/test). To date, the studies generally focus on the targeted quantitation of specific metabolites, 49,50 hardly collecting comprehensive fingerprint information. By harnessing the desirable detection duration, biofluid consumption, and data stability, the NPELDI MS has adequate reliability in comprehensive metabolic profiling and biomarker discovery in the next stage.…”
Section: Resultsmentioning
confidence: 99%
“…An imminent imperative exists to unearth innovative biological insights and prognostic/predictive markers that can adeptly facilitate precision‐based management for individuals grappling with cancer 18,19 . The intracellular signalling pathways governing cancer initiation and progression are highly complex, involving dysregulated expression of various structural and regulatory proteins 20–22 . Elucidating the participation of unexpected proteins, such as TNNT1, in oncogenesis could foster a deeper understanding of tumour biology and facilitate the discovery of novel therapeutic targets.…”
Section: Introductionmentioning
confidence: 99%
“…18,19 The intracellular signalling pathways governing cancer initiation and progression are highly complex, involving dysregulated expression of various structural and regulatory proteins. [20][21][22] Elucidating the participation of unexpected proteins, such as TNNT1, in oncogenesis could foster a deeper understanding of tumour biology and facilitate the discovery of novel therapeutic targets. Tumour immunotherapy has revolutionized cancer treatment by leveraging the immune system's ability to combat malignancies.…”
mentioning
confidence: 99%
“…Lung cancer is currently regarded as the leading cause of cancer-related death worldwide. As NSCLC accounts for about 80% of cases and shows a 5-year survival rate as low as 10–15% [ 1 , 2 ], early diagnosis plays an important role in improving the prognosis and survival [ 3 ].…”
Section: Introductionmentioning
confidence: 99%